Wyniki wyszukiwania - Biblioteka Nauki

1

Antiangiogenic therapy of B16(F10) melanoma metastases in mouse lungs

100%

Cichon T. , Sochanik A. , Szala S.

|

nr Supplement 1

2

Use of conjugate of paclitaxel with PGA in melanoma tumour therapy in mice

100%

Mitrus I. , Cichon T. , Szala S.

|

nr Supplement 4

3

Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affetcs growth of B16-F10 tumors

100%

Mitrus I. , Sochanik A. , Cichon T. , Szala S.

Acta Biochimica Polonica

|

2009

|

tom 56

|

nr 1

161-165

EN

The study aimed to check the effectiveness of anticancer therapy combining a vascular-disruptive drug (combretastatin phosphate, CA4P) and a liposomal formulation of a chemotherapeutic (doxorubicin). CA4P was synthesized in our laboratory according to a previously described procedure. The antivascular drug and long-circulating doxorubicin-loaded liposomes were used to treat B16-F10 murine melanoma experimental tumors. Seventy-four hours after drug administration, a decrease in the number of tumor blood vessels was apparent and necrotic areas within tumors were visible. Combination therapy consisting of alternate administrations of CA4P and liposomal doxorubicin yielded greater inhibition of tumor growth than monotherapies alone. The best therapeutic results were obtained with the antivascular drug administered intratumorally every second day at 50 mg/kg body mass. In the case of combined therapy, the best results were obtained when the vascular-disruptive agent (CA4P) and the antineoplastic agent (liposomal doxorubicin) were administered in alternation.

4

Direct in vivo transfer of plasmid DNA into murine tumors: Effects of endotoxin presence and transgene localization

100%

Budryk M. , Cichon T. , Szala S.

|

nr 3

EN

The purpose of this study was to investigate the effect of endotoxin presence in plasmid DNA preparations on the efficiency of transfection achieved in vivo with B16(F10) and Renca tumors and to determine transgene localization. Our data show that endotoxin markedly decreases the efficiency of transfection. Furthermore, the transgene transferred in vivo can be found in both neoplastic and normal (most likely myofibroblast) cells lying in proximity of the administration site.

5

New chimeric protein ABRaA-VEGF121 is selectively cytotoxic towards cells overexpressing VEGFR2 (KDR) and inhibits growth of primary tumors

88%

Smagur A. , Boyko M. , Biront N. , Cichon T. , Szala S.

|

nr Supplement 4

6

Combination of anticancer peptide (CAMEL) with immunotherapy in B16(F10) murine melanoma tumor therapy

88%

Smolarczyk R. , Cichon T. , Kamysz W. , Nadolny R. , Szala S.

|

nr Supplement 4

7

Combined anticancer therapy using antivascular peptide and folate-targeted liposomes carrying doxorubicin

88%

Sochanik A. S. , Smolarczyk R. , Mitrus I. , Cichon T. , Szala S.

|

nr Supplement 4

8

D-K6L9 peptide combination with IL-12 inhibits the recurrence of tumors in mice

75%

Cichon T. , Smolarczyk R. , Matuszczak S. , Barczyk M. , Jarosz M. , Szala S.

|

nr 4

9

Combined tumor cell-based vaccination and interleukin-12 gene therapy polarizes the tumor microenvironment in mice

75%

Jarosz-Biej M. , Smolarczyk R. , Cichon T. , Kulach N. , Czapla J. , Matuszczak S. , Szala S.

|

tom 63

|

nr 6

10

Antitumor effect of RGD-4C-CG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model

75%

Smolarczyk R. , Cichon T. , Graja K. , Hucz J. , Sochanik A. , Szala S.

|

nr 4

11

Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy

63%

Ciomber A. , Smagur A. , Mitrus I. , Cichon T. , Smolarczyk R. , Sochanik A. , Szala S. , Jarosz M.

Archivum Immunologiae et Therapiae Experimentalis

|

2014

|

tom 62

|

nr 2

12

Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide

63%

Cichon T. , Jarosz M. , Smolarczyk R. , Ogorek B. , Matuszczak S. , Wagner M. , Mitrus I. , Sochanik A. , Jazowiecka-Rakus J. , Szala S.

|

nr 3

EN

One of the preconditions of effective anticancer therapy is efficient transfer of the therapeutic agent (chemotherapeutic) to tumor cells. Fundamental barriers making drug delivery and action difficult include underoxygenation, elevated interstitial pressure, poor and abnormal tumor blood vascular network and acidic tumor milieu. In this study we aimed at developing an optimized scheme of administering a combination of an angiogenesis-inhibiting drug (vasostatin) and a chemotherapeutic (cyclophosphamide) in the therapeutic treatment of mice bearing experimental B16-F10 melanoma tumors. We report that the strongest tumor growth inhibition was observed in mice that received two, three or four vasostatin doses in combination with one injection of cyclophosphamide (i.e., V2 + CTX, V3 + CTX or V4 + CTX schemes). Double administration of vasostatin increases oxygenation of B16-F10 tumors. On the other hand, its five-fold administration lowers tumor oxygenation, breaks down tumor vascular network (increasing hypoxia) and leads in consequence to death of cancer cells and appearance of necrotic areas in the tumor. A decreased cyclophosphamide dose in combination with two doses of vasostatin (V2 + CTX scheme) inhibits tumor growth similarly to a larger dose of cyclophosphamide alone.